Daniel Jagar

Daniel Jagar currently serves as a Senior Manager at KPMG AG Wirtschaftsprüfungsgesellschaft, where he leverages over 12 years of extensive experience in valuation and financial analysis to deliver strategic insights and high-quality advisory services. In his role, Daniel specializes in complex valuation topics, including purchase price allocations under IFRS 3, ASC 805, and German GAAP, as well as impairment testing aligned with IAS 36, ASC 350, and ASC 360 standards. His expertise is particularly valuable in the pharmaceutical and chemical industries, where he has contributed to numerous key projects involving intangible assets, R&D valuation, and fair value assessments.

Daniel’s work often involves conducting fairness opinions in accordance with IDW S8, providing critical support for mergers and acquisitions, divestitures, and corporate restructuring. He is also experienced in squeeze-out valuations and valuation of domination and profit and loss transfer agreements, ensuring compliance with German GAAP and international accounting standards. His deep understanding of life sciences and chemical industry dynamics enables him to assess the unique valuation challenges these sectors face, such as patent portfolios, regulatory approvals, and R&D pipelines.

As a CFA charterholder and German CPA (“Wirtschaftsprüfer”), Daniel combines technical expertise with a pragmatic approach, making him a trusted team player and advisor. His leadership in multidisciplinary teams ensures seamless collaboration on complex projects, from business analysis to financial modeling and auditing. With a strong focus on intangible assets and equity valuation, Daniel continuously enhances KPMG’s capabilities in providing clients with precise, industry-specific valuation insights that support strategic decision-making and compliance in a rapidly evolving market landscape.